Authors: Rosing, H Huinink, WWT Van Gijn, R Rombouts, RFM Bult, A Beijnen, JH

Citation: H. Rosing et al., Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane (R) and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC), EUR J DRUG, 24(1), 1999, pp. 69-77